|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Because of the importance of the CRP gene product in inflammation and its recent association with ischemic heart disease syndromes, this polymorphism may be useful in the association studies of atherosclerosis and its related phenotypes.
|
10721674 |
2000 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because CRP has been associated with clinical events, it could be that elevated CRP may be a stronger marker of thrombotic risk than of the degree of atherosclerosis.
|
11448405 |
2001 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis.
|
11739967 |
2001 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The reciprocal association of adiponectin and CRP levels in both human plasma and adipose tissue might participate in the development of atherosclerosis.
|
12578865 |
2003 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Notably, the risk of atherosclerosis associated with CagA seropositivity was amplified by elevated C-reactive protein levels.
|
12624280 |
2003 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Given the central importance of angiotensin type 1 receptor (AT1-R) in the pathogenesis of atherosclerosis, we examined the effects of CRP on AT1-R expression and kinetics in vascular smooth muscle (VSM) cells.
|
12665485 |
2003 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inflammation was assessed by C-reactive protein and serum amyloid A and atherosclerosis was evaluated from clinical and laboratory data.
|
12686665 |
2003 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, an association between CRP and direct measures of atherosclerosis has not been established clearly.
|
12933535 |
2003 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
By contrast, only 3 of 18 internal mammary and 4 of 12 radial arteries with virtually no atherosclerosis were positive for CRP mRNA.
|
12975260 |
2003 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Turpentine treatment per se did not affect the extent of atherosclerosis in CRP transgenic or nontransgenic apoE-/- mice.
|
14744975 |
2004 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.
|
14744975 |
2004 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because complement-mediated vascular injury participates in atherosclerosis and C-reactive protein (CRP) can activate the complement cascade, we sought to determine whether CRP affects the expression of the protective complement-inhibitory factors on the cell surface of endothelial cells (ECs).
|
14967730 |
2004 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
For clinicians plasma C-reactive protein (CRP) levels are the only widely available tests that provide a tangible link between inflammation and atherosclerosis.
|
15306744 |
2004 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
-717A>G polymorphism of human C-reactive protein gene associated with coronary heart disease in ethnic Han Chinese: the Beijing atherosclerosis study.
|
15517131 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role in atherosclerosis of Fcgamma receptor IIa (FcgammaRIIa), a receptor for immunoglobulin G and for the inflammatory mediator C-reactive protein, is not yet clear.
|
15583733 |
2004 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: clues to the biology of premature atherosclerosis in Hutchinson-Gilford Progeria Syndrome.
|
15756215 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although female apoE knockouts develop atherosclerosis more rapidly than males, the human CRP transgene is under sex hormone control and is expressed at human levels only in males.We therefore studied only male mice.
|
15919817 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because of the oddities of the mouse complement system, however, this may not be a good model to investigate the role of CRP in human atherosclerosis.
|
15920030 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Quantification of atherosclerosis showed that lesion area in E3L/CRP mice was not different from that in E3L mice.
|
15920036 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated effects of cholesterol lowering by therapeutic intervention (2 years) with atorvastatin (80 mg daily) and simvastatin (40 mg daily) on circulating oxidized LDL (absolute level and in proportion to plasma apolipoprotein B) in relation to atherosclerosis progression (carotid intima-media thickness, carotid IMT) and to inflammation (high-sensitivity C-reactive protein, hsCRP) in 115 stable patients with heterozygous familial hypercholesterolemia (FH).
|
16005883 |
2006 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Measurement of serum CRP is recommended for use as an indicator of inflammation and predictor of atherosclerosis.
|
16054696 |
2006 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice.
|
16087790 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we show that mCRP and nCRP have opposite effects on atherosclerosis in ApoE(-/-) mice.
|
16087790 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that there is a link between plasma CRP and the degree of atherosclerosis and that inhibition of plasma CRP may represent a therapeutic modality for the treatment of cardiovascular disease.
|
16192648 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
C-reactive protein (CRP) is a well-documented marker of atherosclerotic cardiovascular disease risk.
|
16266402 |
2005 |